Plain-English translation of NCT07235059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medication called to see if it is safe and well-tolerated in people with chronic kidney disease. Researchers will first test it in healthy volunteers at different dose levels, then test it in people who actually have kidney disease. The goal is to understand how the medication works in the body and whether it could help treat kidney disease.
Chronic kidney disease is a serious condition that affects millions of people, and current treatment options are limited. This medication may offer a new way to help protect kidney function and slow disease progression.
You likely qualify if…
You likely don't qualify if…
The study has three parts that will happen one after another. In Part A, healthy volunteers will receive single doses of the medication (or placebo) at increasing levels to see how safe it is. In Part B, people with kidney disease will receive single doses at increasing levels. In Part C, people with kidney disease will take the medication multiple times over a period of time. You will have regular visits with the research team for blood tests, vital signs checks, heart monitoring, and other assessments to track how your body responds to the treatment.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States
Germany
Phase
Safety & dosing
Sponsor
Novartis Pharmaceuticals
Enrollment target
~112 participants
Started
November 2025
Primary completion
January 2028
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.